AstraZeneca (AZN)
(Real Time Quote from BATS)
$75.27 USD
+4.07 (5.72%)
Updated Apr 25, 2024 01:08 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
Price, Consensus and EPS Surprise
AZN 75.27 +4.07(5.72%)
Will AZN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AZN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AZN
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up
AZN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Q1 GDP Increased Lower Than Expectations
Is "Bad News" Still "Good News" for the Market?
Astrazeneca (AZN) Reports Q1 Earnings: What Key Metrics Have to Say
Other News for AZN
AstraZeneca PLC (AZN) Q1 2024 Earnings Call Transcript
What's Driving AstraZeneca PLC's Surprising 14% Stock Rally?
Sanofi Reports Strong Earnings, Joins Kirby, Sonic Automotive, Union Pacific And Other Big Stocks Moving Higher On Thursday
Biggest stock movers today: LUV, META, IBM, F, and more
AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting